Ornithine and Cyclophosphamide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ornithine (ornithine) and Cyclophosphamide (cyclophosphamide). Common drug interactions include febrile neutropenia among females and disease progression among males.

The phase IV clinical study analyzes what interactions people have when they take Ornithine and Cyclophosphamide. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Ornithine?

Ornithine has active ingredients of ornithine. eHealthMe is studying from 591 Ornithine users. Check the latest studies of Ornithine.

What is Cyclophosphamide?

Cyclophosphamide has active ingredients of cyclophosphamide. It is often used in multiple myeloma. eHealthMe is studying from 185,240 Cyclophosphamide users. Check the latest studies of Cyclophosphamide.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

15 people who take Ornithine and Cyclophosphamide together, and have interactions are studied.

Ornithine and Cyclophosphamide drug interactions.

What are the common drug interactions of Ornithine and Cyclophosphamide, by gender? *:

female:

Febrile neutropenia (fever with reduced white blood cells)
Neutropenia (an abnormally low number of neutrophils)
Abdominal discomfort
Alanine aminotransferase increased
Aspartate aminotransferase increased
Asthenia (weakness)
Gamma-glutamyltransferase increased
Haemangioma of liver (noncancerous, abnormally dense collections of dilated small blood vessels that may occur in liver)
Liver injury
Renal cyst (kidney cyst)

male:

Disease progression
Disease recurrence
Confusional state
Death
Hepatic failure (liver failure)
Hyperglycaemia (high blood sugar)
Hypotension (abnormally low blood pressure)
Melaena (the passage of black, tarry stools)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Platelet count decreased

What are the common drug interactions of Ornithine and Cyclophosphamide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Disease progression
Disease recurrence
Drug hypersensitivity
Drug ineffective
Neoplasm progression (growth of tumour)
Transaminases increased
Vomiting

50-59:

Neutropenia (an abnormally low number of neutrophils)
Death
Hepatic failure (liver failure)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Febrile neutropenia (fever with reduced white blood cells)

60+:

Azotaemia (excess of urea or other nitrogenous compounds in the blood)
Cardiac arrest
Hyperammonaemic encephalopathy (excess of ammonia in the blood, disorder or disease of the brain)
Confusional state
Hyperglycaemia (high blood sugar)
Hypotension (abnormally low blood pressure)
Melaena (the passage of black, tarry stools)
Platelet count decreased
Stupor (lack of critical cognitive function and level of consciousness)

What are the existing conditions these people have? *

Febrile Neutropenia (fever with reduced white blood cells): 8 people, 53.33%
Breast Cancer: 4 people, 26.67%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 3 people, 20.00%
Pain: 1 person, 6.67%
Lymphoplasmacytoid Lymphoma/immunocytoma (a cancer of the lymphatic system): 1 person, 6.67%
Hyperammonaemic Encephalopathy (excess of ammonia in the blood, disorder or disease of the brain): 1 person, 6.67%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 6.67%
Ascites (accumulation of fluid in the abdominal cavity): 1 person, 6.67%
Abdominal Pain: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Ornithine and Cyclophosphamide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously